企業概要
SenesTech, Inc. is primarily engaged in the development and commercialization of proprietary technologies designed to manage animal pest populations through fertility control mechanisms. The enterprise operates within the Basic Materials sector, specifically the Specialty Chemicals industry, which implies a focus on producing specialized chemical compounds rather than bulk commodities. This specialized position is reflected in a relatively small market capitalization of $8.49M and an annual revenue of $2.22M for the trailing twelve months. The company employs a modest workforce of 23 individuals to support its operations, indicating a lean organizational structure typical of early-stage or niche-focused enterprises. The limited scale suggested by the market cap and revenue figures positions the firm as a micro-cap entity with a distinct focus on a specific technological solution rather than broad market diversification.
財務健全性
The company reported revenue of $2.22M over the trailing twelve months, yet it incurred a net income loss of $-6,383,000, revealing a significant divergence where operating expenses and costs far exceeded gross profitability. This substantial gap indicates a cost structure that is currently unable to generate profit from sales, resulting in an operating margin of -446.8% and a profit margin of -287.4%. Despite these operational losses, the firm maintains a strong cash position of $8.57M, which stands in contrast to its total debt obligation of $2.68M. The company's financial flexibility is constrained by negative free cash flow of $-3,711,375, suggesting that current operations are burning through cash reserves rather than generating liquidity. Return on Equity stands at -105.7% and Return on Assets at -50.4%, metrics that reveal management has yet to achieve positive returns on shareholder capital or the asset base. The debt-to-equity ratio is recorded at 27.98, yet the current ratio is an exceptionally high 12.61, indicating that short-term assets significantly outweigh short-term liabilities and providing a buffer against immediate liquidity crises.
バリュエーション評価
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of net income, while the forward P/E is -0.36. The discrepancy between a non-existent trailing multiple and a negative forward multiple implies that the market is pricing in a long period of negative earnings before profitability returns. The price-to-book ratio is 0.87, indicating that the market values the company at less than its book value, which often suggests a market discount or that the asset base is not fully capitalized at current market prices. Alternative valuation metrics such as the price-to-sales ratio of 3.82 and an EV/EBITDA of -0.41 are utilized to assess value in the absence of earnings, suggesting the company is valued based on its revenue generation potential despite current unprofitability. The stock's trading range over the past year spans from a 52-week low of $1.31 to a high of $6.24. Without a specific current share price provided in the facts, the relative position to this range cannot be calculated, but the wide spread of $4.93 between the high and low highlights significant price volatility. The beta value of 0.25 indicates that the stock exhibits low price volatility relative to the broader market, moving with much less intensity than the general equity index.
Growth & Income
Revenue growth year-over-year has declined by -16.0%, while earnings growth is N/A due to the company's persistent losses. The contraction in revenue suggests a shrinking top line, and since the company is unprofitable, there are no earnings to grow faster than revenue; rather, the firm is operating in a territory of declining sales and deepening losses. As a non-dividend payer with a payout ratio of 0.0% and no dividend yield, the company does not distribute income to shareholders. Instead, the firm reinvests its limited cash flow, or lacks thereof, into its operations and technology development rather than paying dividends. The overall growth and income profile is characterized by declining revenue, negative cash generation, and a total absence of dividend income, reflecting the high-risk nature of a speculative micro-cap stock in the specialty chemicals sector.